-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Decreases By 10.9%
Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Decreases By 10.9%
Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) was the recipient of a large decline in short interest during the month of August. As of August 15th, there was short interest totalling 87,300 shares, a decline of 10.9% from the July 31st total of 98,000 shares. Based on an average daily trading volume, of 56,000 shares, the days-to-cover ratio is currently 1.6 days. Currently, 1.0% of the company's stock are sold short.
Analyst Ratings Changes
Separately, Royal Bank of Canada dropped their target price on Avalo Therapeutics from $24.00 to $21.00 in a research note on Monday, July 11th.
Get Avalo Therapeutics alerts:Avalo Therapeutics Stock Performance
Avalo Therapeutics stock opened at $4.82 on Wednesday. The company has a current ratio of 0.98, a quick ratio of 0.97 and a debt-to-equity ratio of 5.23. The business's 50-day simple moving average is $6.11 and its two-hundred day simple moving average is $6.53. Avalo Therapeutics has a fifty-two week low of $2.42 and a fifty-two week high of $38.88.
Avalo Therapeutics (NASDAQ:AVTX – Get Rating) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($1.38) earnings per share for the quarter, beating the consensus estimate of ($1.77) by $0.39. Avalo Therapeutics had a negative return on equity of 449.27% and a negative net margin of 1,896.95%. As a group, sell-side analysts forecast that Avalo Therapeutics will post -2.02 EPS for the current year.Institutional Trading of Avalo Therapeutics
Large investors have recently added to or reduced their stakes in the company. Northern Trust Corp boosted its stake in shares of Avalo Therapeutics by 3.1% in the fourth quarter. Northern Trust Corp now owns 533,578 shares of the company's stock worth $907,000 after buying an additional 16,276 shares during the last quarter. Freestone Capital Holdings LLC purchased a new stake in shares of Avalo Therapeutics in the fourth quarter worth about $34,000. LGL Partners LLC purchased a new stake in shares of Avalo Therapeutics in the fourth quarter worth about $49,000. Leo Brokerage LLC purchased a new stake in shares of Avalo Therapeutics in the first quarter worth about $45,000. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Avalo Therapeutics by 23.8% in the second quarter. Goldman Sachs Group Inc. now owns 649,653 shares of the company's stock worth $324,000 after buying an additional 124,769 shares during the last quarter.
Avalo Therapeutics Company Profile
(Get Rating)
Avalo Therapeutics, Inc, a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome.
Further Reading
- Get a free copy of the StockNews.com research report on Avalo Therapeutics (AVTX)
- How the Pandemic Forced F5 to Flex its Software Side
- Shock Absorbers: 3 Low Volatility Dividend Stocks for Bumpy Times
- The Retail Sector: Winners And Losers From Q2 Earnings
- Can Targa Continue Rallying To Meet Its Price Target?
- Is Unity Software Ready To Rally After Rejecting AppLovin Offer?
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) was the recipient of a large decline in short interest during the month of August. As of August 15th, there was short interest totalling 87,300 shares, a decline of 10.9% from the July 31st total of 98,000 shares. Based on an average daily trading volume, of 56,000 shares, the days-to-cover ratio is currently 1.6 days. Currently, 1.0% of the company's stock are sold short.
阿瓦洛治疗公司(纳斯达克代码:AVTX-GET评级)是8月份空头股数价格大幅下降的接受者。截至8月15日,空头股数共有87,300股,较7月31日的98,000股下降10.9%。以日均成交量5.6万股计算,目前天数与回补比率为1.6日。目前,该公司1.0%的股票被卖空。
Analyst Ratings Changes
分析师评级发生变化
Separately, Royal Bank of Canada dropped their target price on Avalo Therapeutics from $24.00 to $21.00 in a research note on Monday, July 11th.
另外,加拿大皇家银行在7月11日星期一的一份研究报告中将阿瓦洛治疗公司的目标价从24.00美元下调至21.00美元。
Avalo Therapeutics Stock Performance
Avalo治疗公司股票表现
Avalo Therapeutics stock opened at $4.82 on Wednesday. The company has a current ratio of 0.98, a quick ratio of 0.97 and a debt-to-equity ratio of 5.23. The business's 50-day simple moving average is $6.11 and its two-hundred day simple moving average is $6.53. Avalo Therapeutics has a fifty-two week low of $2.42 and a fifty-two week high of $38.88.
周三,Avalo治疗公司的股票开盘报4.82美元。该公司的流动比率为0.98,速动比率为0.97,债务权益比率为5.23。该业务的50日简单移动均线切入位为6.11美元,200日简单移动均线切入位为6.53美元。Avalo Treateutics的股价为52周低点2.42美元,52周高点为38.88美元。
Institutional Trading of Avalo Therapeutics
Avalo治疗公司的机构交易
Large investors have recently added to or reduced their stakes in the company. Northern Trust Corp boosted its stake in shares of Avalo Therapeutics by 3.1% in the fourth quarter. Northern Trust Corp now owns 533,578 shares of the company's stock worth $907,000 after buying an additional 16,276 shares during the last quarter. Freestone Capital Holdings LLC purchased a new stake in shares of Avalo Therapeutics in the fourth quarter worth about $34,000. LGL Partners LLC purchased a new stake in shares of Avalo Therapeutics in the fourth quarter worth about $49,000. Leo Brokerage LLC purchased a new stake in shares of Avalo Therapeutics in the first quarter worth about $45,000. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Avalo Therapeutics by 23.8% in the second quarter. Goldman Sachs Group Inc. now owns 649,653 shares of the company's stock worth $324,000 after buying an additional 124,769 shares during the last quarter.
大型投资者最近增持或减持了该公司的股份。北方信托公司在第四季度增持了Avalo治疗公司3.1%的股份。Northern Trust Corp目前持有535,578股该公司股票,价值90.7万美元,此前该公司在上一季度又购买了16,276股。Frestone Capital Holdings LLC在第四季度购买了Avalo治疗公司价值约3.4万美元的新股份。LGL Partners LLC在第四季度购买了Avalo治疗公司的新股份,价值约49,000美元。Leo Brokerage LLC在第一季度购买了价值约4.5万美元的Avalo治疗公司的新股份。最后,高盛股份有限公司在第二季度增持了阿瓦洛治疗公司23.8%的股份。高盛股份有限公司目前持有该公司649,653股股票,价值324,000美元,该公司在上个季度又购买了124,769股。
Avalo Therapeutics Company Profile
Avalo治疗公司简介
(Get Rating)
(获取评级)
Avalo Therapeutics, Inc, a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome.
Avalo Treateutics,Inc.是一家临床阶段的精密药物公司,为免疫学、免疫肿瘤学和罕见遗传病方面未得到满足的临床需求的患者发现、开发和商业化靶向疗法。该公司开发了AVTX-002,这是一种完全人类抗光的单抗,正在进行第二阶段临床试验,用于治疗非嗜酸性哮喘以及炎症性肠道疾病,包括中到重度克罗恩病和溃疡性结肠炎;以及第三阶段临床试验,用于治疗新冠肺炎急性呼吸窘迫综合征。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Avalo Therapeutics (AVTX)
- How the Pandemic Forced F5 to Flex its Software Side
- Shock Absorbers: 3 Low Volatility Dividend Stocks for Bumpy Times
- The Retail Sector: Winners And Losers From Q2 Earnings
- Can Targa Continue Rallying To Meet Its Price Target?
- Is Unity Software Ready To Rally After Rejecting AppLovin Offer?
- 免费获取StockNews.com关于Avalo治疗公司(AVTX)的研究报告
- 大流行如何迫使F5调整其软件方面
- 减震器:颠簸时代的3只低波动率红利股票
- 零售业:第二季度收益的赢家和输家
- Targa能否继续反弹以实现其价格目标?
- 在拒绝了AppLovin的报价后,Unity Software准备好重整旗鼓了吗?
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《阿瓦洛治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Avalo治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧